Dolutegravir vs VH4524184
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV integrase · full HIV pipeline
Dolutegravir · Tivicay / Triumeq / Dovato / Juluca (component)
Marketed by GlaxoSmithKline and partners
NCT01263015 · Phase 3 · completed
This was a randomized, quadruple-blind, active-controlled phase 3 trial in 833 participants comparing dolutegravir plus abacavir/lamivudine to Atripla. The primary endpoint of virologic suppression (<50 copies/mL) at week 48 was a hard clinical measure, and the comparison was statistically significant in favor of dolutegravir (88% vs 81%, p=0.003), with the confidence interval excluding zero. The trial was adequately powered and the primary outcome was met, supporting a strong evidence grade.
Next expected readout: November 2026 · NCT04892654 (registry estimate)
Reported efficacy
Proportion of Subjects Responding Based on Plasma HIV-1 RNA <50 c/mL at Week 48: Week 48 HIV-1 RNA <50 c/mL: 88% with dolutegravir plus abacavir/lamivudine vs 81% with Atripla; difference 7.3 percentage points (95% CI 2.3 to 12.2; p=0.003). (met)
Result source: NCT01263015
VH4524184
Developed by ViiV Healthcare
NCT06214052 · Phase 2 · completed
The study was randomized and double-blind with matching placebo, but it was very small, with 6, 6, and 7 participants receiving VH4524184 doses and only 3 receiving placebo. Its primary endpoint was a surrogate measure of plasma HIV-1 RNA change, and although the reported mean changes favored the medium and high doses, statistical significance was not reported.
Next expected readout: October 2027 · NCT07202546 (registry estimate)
Reported efficacy
Monotherapy: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) (At Day 10): Monotherapy: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) (At Day 10): VH4524184 Dose 1 -1.17 Copies per milliliter (copies/mL) (Standard Deviation 0.46) | VH4524184 Dose 2 -2.15 Copies per milliliter (copies/mL) (Standard Deviation 0.254) | VH4524184 Dose 3 -2.31 Copies per milliliter (copies/mL) (Standard Deviation 0.463) vs Placebo -0.28 Copies per milliliter (copies/mL) (Standard Deviation 0.37) (unclear)
Result source: NCT06214052
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Dolutegravir | VH4524184 |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | 88% vs 85%vs RTGNCT0122782412 other results
| —Not reported |
| HIV-1 RNA 50 copies/mL or more (week 48) | —Not posted · NCT01837277 | —Not reported |
| CD4 count, change (week 48) | 163 vs 174−11 vs placeboNCT0156889244 other results
| —Not reported |
HIV-1 RNA below 50 copies/mL (week 48)
- Dolutegravir
- 88% vs 85%vs RTGNCT01227824
12 other results
- 90% vs 83% NCT01449929
- 88% vs 81% NCT01263015
- 90% vs 93% NCT02831673
- 93% vs 94% NCT02831764
- 71% vs 63% NCT01263015
- 77% vs 70% NCT01263015
- 79% vs 83% NCT02831673
- 84% vs 84% NCT02831764
- 84% vs 89% NCT02831673
- 88% vs 90% NCT02831764
- 92% vs 93% NCT02831673
- 94% vs 94% NCT02831764
- VH4524184
- —Not reported
HIV-1 RNA 50 copies/mL or more (week 48)
- Dolutegravir
- —Not posted · NCT01837277
- VH4524184
- —Not reported
CD4 count, change (week 48)
- Dolutegravir
- 163 vs 174−11 vs placeboNCT01568892
44 other results
- 170 vs 146 NCT01568892
- 115 vs 156 NCT01568892
- 90.5 vs 125.5 NCT01568892
- 48 vs 135.5 NCT01568892
- 39 vs 117 NCT01568892
- 292.2 vs 286.2 NCT01227824
- 281.3 vs 292.9 NCT01227824
- 247.8 vs 278.6 NCT01227824
- 247.8 vs 264.2 NCT01227824
- 238.9 vs 257.5 NCT01227824
- 248.8 vs 230.7 NCT01910402
- 224.1 vs 239.8 NCT01227824
- 230.7 vs 191.4 NCT01910402
- 223.4 vs 241.3 NCT01227824
- 199.3 vs 204.2 NCT01227824
- 200.6 vs 163 NCT01910402
- 378.5 vs 331.6 NCT01263015
- 379.5 vs 333.3 NCT01263015
- 377.9 vs 327.2 NCT01263015
- 347 vs 311 NCT01263015
- 349.3 vs 298.9 NCT01263015
- 322.6 vs 286 NCT01263015
- 315.2 vs 272.1 NCT01263015
- 306.1 vs 269.6 NCT01263015
- 271.3 vs 235.3 NCT01263015
- 267.5 vs 209.5 NCT01263015
- 265.5 vs 216.2 NCT01263015
- 250.5 vs 208.1 NCT01263015
- 216.9 vs 177.8 NCT01263015
- 301.8 vs 303.2 NCT02831673
- 301.7 vs 296.6 NCT02831764
- 264.7 vs 253.8 NCT02831673
- 272 vs 264.6 NCT02831764
- 265 vs 230 NCT02259127
- 311 vs 230 NCT02259127
- 228 vs 230 NCT02259127
- 222.2 vs 217.7 NCT02831673
- 225.7 vs 217.2 NCT02831764
- 192.2 vs 175.1 NCT02831673
- 188.8 vs 163.2 NCT02831764
- 72 vs 230 NCT02259127
- 39 vs 28 NCT02263326
- 88 vs 75 NCT03991013
- 111 vs 101 NCT03851588
- VH4524184
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. Dolutegravir: 5 of 5 rows · VH4524184: 4 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Dolutegravir | VH4524184 |
|---|---|---|
| CD4+ absolute change · cells/uL Induction | 214.7 vs 174.1 EFV/TDF/FTC cells/uL @ 16wk50 mg plus 600/300 mg once dailya,b,c NCT01263015 · Phase 3 · combination · HIV · phase 3 2 other source trials155.1 vs 173 RTG cells/uL @ 16wk50 mg Once a Day NCT01227824 · Phase 3 · HIV · phase 3 76.5 vs 70 placebo cells/uL @ 16wk50 mg BID NCT01568892 · Phase 3 · registry result, not featured evidence | 131.333 vs 63.667 placebo cells/uL @ 1.43wkDose 1d,a,b,c NCT06214052 · Phase 2 · combination · HIV · phase 2 show 2 more doses68.667 vs 63.667 placebo cells/uL @ 1.43wkDose 2 NCT06214052 · Phase 2 · combination · HIV · phase 2 47 vs 63.667 placebo cells/uL @ 1.43wkDose 3 NCT06214052 · Phase 2 · combination · HIV · phase 2 |
| Dropout rate | 17.4%50 mg plus 600/300 mg once dailye NCT01263015 · Phase 3 · combination · HIV · phase 3 show 41 more results26%50 mg Once a Day NCT01227824 · Phase 3 · HIV · phase 3 —50 mg Once a Day NCT01227824 · Phase 3 · HIV · phase 3 13.6%50 mg once daily NCT01449929 · Phase 3 —50 mg once daily NCT01449929 · Phase 3 —50 mg once daily NCT01449929 · Phase 3 31.1%50 mg BID NCT01328041 · Phase 3 8.5% NCT04880395 · Phase 4 · registry result, not featured evidence · combination 10.7% NCT04585737 · Phase 4 · registry result, not featured evidence 25.6%Abacavir/Dolutegravir/Lamivudine(A NCT03016533 · Phase 3 · registry result, not featured evidence · combination 13.1%Dolutegravir (DTG) NCT03016533 · Phase 3 · registry result, not featured evidence —DTG 50 mg/ABC 600 mg/3TC 300 mg QD NCT01910402 · Phase 3 · registry result, not featured evidence 17.6%DTG 50 mg/ABC 600 mg/3TC 300 mg QD NCT01910402 · Phase 3 · registry result, not featured evidence —DTG + 3TC-Continuation Phase NCT02831673 · Phase 3 · registry result, not featured evidence · combination 16.2%DTG + 3TC-Double Blind Phase NCT02831673 · Phase 3 · registry result, not featured evidence · combination —DTG + 3TC-Double-blind Phase + Ope NCT02831673 · Phase 3 · registry result, not featured evidence · combination —DTG + 3TC - Continuation Phase NCT02831764 · Phase 3 · registry result, not featured evidence · combination 11.4%DTG + 3TC - Double-blind Phase NCT02831764 · Phase 3 · registry result, not featured evidence · combination —DTG + 3TC - Double-blind Phase + O NCT02831764 · Phase 3 · registry result, not featured evidence · combination 7.8%Arm 1: Maternal DTG+FTC/TAF NCT03048422 · Phase 3 · registry result, not featured evidence · combination 4.7%Arm 2: Maternal DTG+FTC/TDF NCT03048422 · Phase 3 · registry result, not featured evidence · combination 2.3% NCT02263326 · Phase 3 · registry result, not featured evidence · combination 15.4%50 mg OD NCT01499199 · Phase 3 · registry result, not featured evidence 0%50 mg BID NCT01568892 · Phase 3 · registry result, not featured evidence —50mg BID NCT01568892 · Phase 3 · registry result, not featured evidence 0%Dolutegravir (<14kg Cohort) NCT02259127 · Phase 2/3 · registry result, not featured evidence 0%Dolutegravir (>=14kg Cohort) NCT02259127 · Phase 2/3 · registry result, not featured evidence —Dolutegravir - ODYSSEY A (>=14kg C NCT02259127 · Phase 2/3 · registry result, not featured evidence —Dolutegravir - ODYSSEY B (>=14kg C NCT02259127 · Phase 2/3 · registry result, not featured evidence 23.9% NCT01837277 · Phase 2/3 · registry result, not featured evidence 0%50 mg od NCT02245022 · Phase 2/3 · registry result, not featured evidence 6.7%50 mg BID NCT05630872 · Phase 2 · registry result, not featured evidence 1.5% NCT03991013 · Phase 2 · registry result, not featured evidence 3.8% NCT03851588 · Phase 2 · registry result, not featured evidence —Cohort 1 Stratum 1A NCT05406583 · Phase 1 · registry result, not featured evidence —Cohort 1 Stratum 1B NCT05406583 · Phase 1 · registry result, not featured evidence —Cohort 1 Stratum 1C NCT05406583 · Phase 1 · registry result, not featured evidence —Cohort 2 Stratum 2A NCT05406583 · Phase 1 · registry result, not featured evidence —Cohort 2 Stratum 2B NCT05406583 · Phase 1 · registry result, not featured evidence —Arm 1 Dolutegravir NCT04771754 · Phase 1 · registry result, not featured evidence —Arm 2 Dolutegravir NCT04771754 · Phase 1 · registry result, not featured evidence 0%50mg/25mg NCT03984838 · Phase 1 · registry result, not featured evidence | 0%Dose 1 NCT06214052 · Phase 2 · combination · HIV · phase 2 show 8 more results—Dose 1 NCT06214052 · Phase 2 · combination · HIV · phase 2 —Dose 1 NCT06214052 · Phase 2 · combination · HIV · phase 2 0%Dose 2 NCT06214052 · Phase 2 · combination · HIV · phase 2 —Dose 2 NCT06214052 · Phase 2 · combination · HIV · phase 2 —Dose 2 NCT06214052 · Phase 2 · combination · HIV · phase 2 0%Dose 3 NCT06214052 · Phase 2 · combination · HIV · phase 2 —Dose 3 NCT06214052 · Phase 2 · combination · HIV · phase 2 —Dose 3 NCT06214052 · Phase 2 · combination · HIV · phase 2 |
| Discontinued due to AEs | 3.1%50 mg plus 600/300 mg once dailye NCT01263015 · Phase 3 · combination · HIV · phase 3 show 41 more results2.9%50 mg Once a Day NCT01227824 · Phase 3 · HIV · phase 3 —50 mg Once a Day NCT01227824 · Phase 3 · HIV · phase 3 2.1%50 mg once daily NCT01449929 · Phase 3 —50 mg once daily NCT01449929 · Phase 3 —50 mg once daily NCT01449929 · Phase 3 3.8%50 mg BID NCT01328041 · Phase 3 — NCT04880395 · Phase 4 · registry result, not featured evidence · combination — NCT04585737 · Phase 4 · registry result, not featured evidence —Abacavir/Dolutegravir/Lamivudine(A NCT03016533 · Phase 3 · registry result, not featured evidence · combination —Dolutegravir (DTG) NCT03016533 · Phase 3 · registry result, not featured evidence —DTG 50 mg/ABC 600 mg/3TC 300 mg QD NCT01910402 · Phase 3 · registry result, not featured evidence 4%DTG 50 mg/ABC 600 mg/3TC 300 mg QD NCT01910402 · Phase 3 · registry result, not featured evidence —DTG + 3TC-Continuation Phase NCT02831673 · Phase 3 · registry result, not featured evidence · combination 2.8%DTG + 3TC-Double Blind Phase NCT02831673 · Phase 3 · registry result, not featured evidence · combination —DTG + 3TC-Double-blind Phase + Ope NCT02831673 · Phase 3 · registry result, not featured evidence · combination —DTG + 3TC - Continuation Phase NCT02831764 · Phase 3 · registry result, not featured evidence · combination 2.8%DTG + 3TC - Double-blind Phase NCT02831764 · Phase 3 · registry result, not featured evidence · combination —DTG + 3TC - Double-blind Phase + O NCT02831764 · Phase 3 · registry result, not featured evidence · combination —Arm 1: Maternal DTG+FTC/TAF NCT03048422 · Phase 3 · registry result, not featured evidence · combination —Arm 2: Maternal DTG+FTC/TDF NCT03048422 · Phase 3 · registry result, not featured evidence · combination — NCT02263326 · Phase 3 · registry result, not featured evidence · combination 7.7%50 mg OD NCT01499199 · Phase 3 · registry result, not featured evidence —50 mg BID NCT01568892 · Phase 3 · registry result, not featured evidence —50mg BID NCT01568892 · Phase 3 · registry result, not featured evidence —Dolutegravir (<14kg Cohort) NCT02259127 · Phase 2/3 · registry result, not featured evidence —Dolutegravir (>=14kg Cohort) NCT02259127 · Phase 2/3 · registry result, not featured evidence —Dolutegravir - ODYSSEY A (>=14kg C NCT02259127 · Phase 2/3 · registry result, not featured evidence —Dolutegravir - ODYSSEY B (>=14kg C NCT02259127 · Phase 2/3 · registry result, not featured evidence — NCT01837277 · Phase 2/3 · registry result, not featured evidence —50 mg od NCT02245022 · Phase 2/3 · registry result, not featured evidence —50 mg BID NCT05630872 · Phase 2 · registry result, not featured evidence — NCT03991013 · Phase 2 · registry result, not featured evidence — NCT03851588 · Phase 2 · registry result, not featured evidence —Cohort 1 Stratum 1A NCT05406583 · Phase 1 · registry result, not featured evidence —Cohort 1 Stratum 1B NCT05406583 · Phase 1 · registry result, not featured evidence —Cohort 1 Stratum 1C NCT05406583 · Phase 1 · registry result, not featured evidence —Cohort 2 Stratum 2A NCT05406583 · Phase 1 · registry result, not featured evidence —Cohort 2 Stratum 2B NCT05406583 · Phase 1 · registry result, not featured evidence —Arm 1 Dolutegravir NCT04771754 · Phase 1 · registry result, not featured evidence —Arm 2 Dolutegravir NCT04771754 · Phase 1 · registry result, not featured evidence —50mg/25mg NCT03984838 · Phase 1 · registry result, not featured evidence | —Dose 1 NCT06214052 · Phase 2 · combination · HIV · phase 2 show 8 more results—Dose 1 NCT06214052 · Phase 2 · combination · HIV · phase 2 —Dose 1 NCT06214052 · Phase 2 · combination · HIV · phase 2 —Dose 2 NCT06214052 · Phase 2 · combination · HIV · phase 2 —Dose 2 NCT06214052 · Phase 2 · combination · HIV · phase 2 —Dose 2 NCT06214052 · Phase 2 · combination · HIV · phase 2 —Dose 3 NCT06214052 · Phase 2 · combination · HIV · phase 2 —Dose 3 NCT06214052 · Phase 2 · combination · HIV · phase 2 —Dose 3 NCT06214052 · Phase 2 · combination · HIV · phase 2 |
| Serious AEs | 15.7%50 mg plus 600/300 mg once dailye NCT01263015 · Phase 3 · combination · HIV · phase 3 show 41 more results10%50 mg Once a Day NCT01227824 · Phase 3 · HIV · phase 3 6.2%50 mg Once a Day NCT01227824 · Phase 3 · HIV · phase 3 —50 mg once daily NCT01449929 · Phase 3 14.9%50 mg once daily NCT01449929 · Phase 3 3.3%50 mg once daily NCT01449929 · Phase 3 25.1%50 mg BID NCT01328041 · Phase 3 9.9% NCT04880395 · Phase 4 · registry result, not featured evidence · combination 8.1% NCT04585737 · Phase 4 · registry result, not featured evidence 7.7%Abacavir/Dolutegravir/Lamivudine(A NCT03016533 · Phase 3 · registry result, not featured evidence · combination 8.2%Dolutegravir (DTG) NCT03016533 · Phase 3 · registry result, not featured evidence 8.7%DTG 50 mg/ABC 600 mg/3TC 300 mg QD NCT01910402 · Phase 3 · registry result, not featured evidence 4.8%DTG 50 mg/ABC 600 mg/3TC 300 mg QD NCT01910402 · Phase 3 · registry result, not featured evidence 2.1%DTG + 3TC-Continuation Phase NCT02831673 · Phase 3 · registry result, not featured evidence · combination —DTG + 3TC-Double Blind Phase NCT02831673 · Phase 3 · registry result, not featured evidence · combination 10.4%DTG + 3TC-Double-blind Phase + Ope NCT02831673 · Phase 3 · registry result, not featured evidence · combination 3.6%DTG + 3TC - Continuation Phase NCT02831764 · Phase 3 · registry result, not featured evidence · combination —DTG + 3TC - Double-blind Phase NCT02831764 · Phase 3 · registry result, not featured evidence · combination 10.8%DTG + 3TC - Double-blind Phase + O NCT02831764 · Phase 3 · registry result, not featured evidence · combination 18%Arm 1: Maternal DTG+FTC/TAF NCT03048422 · Phase 3 · registry result, not featured evidence · combination 18.1%Arm 2: Maternal DTG+FTC/TDF NCT03048422 · Phase 3 · registry result, not featured evidence · combination 2.3% NCT02263326 · Phase 3 · registry result, not featured evidence · combination 15.4%50 mg OD NCT01499199 · Phase 3 · registry result, not featured evidence —50 mg BID NCT01568892 · Phase 3 · registry result, not featured evidence 35.7%50mg BID NCT01568892 · Phase 3 · registry result, not featured evidence 26.2%Dolutegravir (<14kg Cohort) NCT02259127 · Phase 2/3 · registry result, not featured evidence 10%Dolutegravir (>=14kg Cohort) NCT02259127 · Phase 2/3 · registry result, not featured evidence 14.9%Dolutegravir - ODYSSEY A (>=14kg C NCT02259127 · Phase 2/3 · registry result, not featured evidence 6.1%Dolutegravir - ODYSSEY B (>=14kg C NCT02259127 · Phase 2/3 · registry result, not featured evidence 9.8% NCT01837277 · Phase 2/3 · registry result, not featured evidence 6.9%50 mg od NCT02245022 · Phase 2/3 · registry result, not featured evidence 6.7%50 mg BID NCT05630872 · Phase 2 · registry result, not featured evidence 3.1% NCT03991013 · Phase 2 · registry result, not featured evidence 0% NCT03851588 · Phase 2 · registry result, not featured evidence 0%Cohort 1 Stratum 1A NCT05406583 · Phase 1 · registry result, not featured evidence 0%Cohort 1 Stratum 1B NCT05406583 · Phase 1 · registry result, not featured evidence 0%Cohort 1 Stratum 1C NCT05406583 · Phase 1 · registry result, not featured evidence 7.1%Cohort 2 Stratum 2A NCT05406583 · Phase 1 · registry result, not featured evidence 0%Cohort 2 Stratum 2B NCT05406583 · Phase 1 · registry result, not featured evidence 0%Arm 1 Dolutegravir NCT04771754 · Phase 1 · registry result, not featured evidence 0%Arm 2 Dolutegravir NCT04771754 · Phase 1 · registry result, not featured evidence 0%50mg/25mg NCT03984838 · Phase 1 · registry result, not featured evidence | —Dose 1 NCT06214052 · Phase 2 · combination · HIV · phase 2 show 8 more results0%Dose 1 NCT06214052 · Phase 2 · combination · HIV · phase 2 0%Dose 1 NCT06214052 · Phase 2 · combination · HIV · phase 2 —Dose 2 NCT06214052 · Phase 2 · combination · HIV · phase 2 0%Dose 2 NCT06214052 · Phase 2 · combination · HIV · phase 2 0%Dose 2 NCT06214052 · Phase 2 · combination · HIV · phase 2 —Dose 3 NCT06214052 · Phase 2 · combination · HIV · phase 2 0%Dose 3 NCT06214052 · Phase 2 · combination · HIV · phase 2 0%Dose 3 NCT06214052 · Phase 2 · combination · HIV · phase 2 |
| Most frequent reported AEs | 50 mg plus 600/300 mg once dailye diarrhoea 22.7% nasopharyngitis 20.8% insomnia 17.9% NCT01263015 · Phase 3 · combination · HIV · phase 3 show 31 more results50 mg Once a Day upper respiratory tract infection 8% syphilis 7.1% viral upper respiratory tract infection 7.1% NCT01227824 · Phase 3 · HIV · phase 3 50 mg once daily viral upper respiratory tract infection 4.1% gastroenteritis 2.4% asthenia 1.6% NCT01449929 · Phase 3 insomnia/nightmares 3.9% alopecia 2% itching/rash/prurigo 2% NCT04880395 · Phase 4 · registry result, not featured evidence · combination upper respiratory tract infection 8.7% headache 8.1% urinary tract infection 6% NCT01910402 · Phase 3 · registry result, not featured evidence nausea 18.5% headache 11.7% diarrhoea 9.3% NCT01910402 · Phase 3 · registry result, not featured evidence covid-19 6.9% suspected covid-19 3.4% headache 3% NCT02831673 · Phase 3 · registry result, not featured evidence · combination headache 14.3% diarrhoea 14% nasopharyngitis 13.8% NCT02831673 · Phase 3 · registry result, not featured evidence · combination covid-19 6% syphilis 4% respiratory tract infection viral 3.2% NCT02831764 · Phase 3 · registry result, not featured evidence · combination diarrhoea 13.6% upper respiratory tract infection 13.1% nasopharyngitis 12.2% NCT02831764 · Phase 3 · registry result, not featured evidence · combination creatinine renal clearance decreased 83.9% blood creatinine increased 78.3% haemoglobin decreased 3.7% NCT03048422 · Phase 3 · registry result, not featured evidence · combination creatinine renal clearance decreased 89.8% blood creatinine increased 83.3% haemoglobin decreased 9.3% NCT03048422 · Phase 3 · registry result, not featured evidence · combination grade 3 bilirubinemia 0% NCT02263326 · Phase 3 · registry result, not featured evidence · combination 50 mg OD headache 53.8% upper respiratory tract infection 38.5% diarrhoea 30.8% NCT01499199 · Phase 3 · registry result, not featured evidence 50mg BID diarrhoea 21.4% (placebo 12.5%) headache 21.4% (placebo 6.3%) lymphadenopathy 21.4% (placebo 0%) NCT01568892 · Phase 3 · registry result, not featured evidence cns disturbances 0% NCT01837277 · Phase 2/3 · registry result, not featured evidence 50 mg BID abnormal loss of weight 10% blood pressure increased 10% headache 10% NCT05630872 · Phase 2 · registry result, not featured evidence acute psychosis 1.5% (placebo 0%) incident pulmonary tuberculosis 1.5% (placebo 0%) acute kidney injury 0% (placebo 3.1%) NCT03991013 · Phase 2 · registry result, not featured evidence insomnia 5.7% (placebo 0%) NCT03851588 · Phase 2 · registry result, not featured evidence haemoglobin decreased 33.3% alanine aminotransferase increased 16.7% aspartate aminotransferase increased 16.7% NCT05406583 · Phase 1 · registry result, not featured evidence haemoglobin decreased 50% alanine aminotransferase increased 16.7% blood bilirubin increased 16.7% NCT05406583 · Phase 1 · registry result, not featured evidence haemoglobin decreased 83.3% neutrophil count decreased 50% acne infantile 16.7% NCT05406583 · Phase 1 · registry result, not featured evidence haemoglobin decreased 42.9% blood bilirubin increased 35.7% dermatitis diaper 21.4% NCT05406583 · Phase 1 · registry result, not featured evidence haemoglobin decreased 56.3% neutrophil count decreased 31.3% blood bilirubin increased 25% NCT05406583 · Phase 1 · registry result, not featured evidence hypokalaemia 71.4% (placebo 71.4%) hypoglycaemia 42.9% (placebo 71.4%) vivid dreams 28.6% (placebo 0%) NCT04771754 · Phase 1 · registry result, not featured evidence hypokalaemia 62.5% (placebo 71.4%) cold 25% (placebo 14.3%) bloating 12.5% (placebo 0%) NCT04771754 · Phase 1 · registry result, not featured evidence 50mg/25mg headache 6.3% vessel puncture site bruise 6.3% vomiting 6.3% NCT03984838 · Phase 1 · registry result, not featured evidence | Dose 1 abdominal distension 16.7% (placebo 0%) acute sinusitis 16.7% (placebo 0%) dermatitis 16.7% (placebo 0%) NCT06214052 · Phase 2 · combination · HIV · phase 2 show 5 more resultsDose 1 dermatitis 16.7% (placebo 0%) diarrhoea 16.7% (placebo 33.3%) abdominal distension 0% (placebo 0%) NCT06214052 · Phase 2 · combination · HIV · phase 2 Dose 2 alanine aminotransferase increased 16.7% (placebo 0%) gastroenteritis 16.7% (placebo 33.3%) hypertension 16.7% (placebo 0%) NCT06214052 · Phase 2 · combination · HIV · phase 2 Dose 2 amylase increased 16.7% (placebo 0%) fatigue 16.7% (placebo 0%) lipase increased 16.7% (placebo 0%) NCT06214052 · Phase 2 · combination · HIV · phase 2 Dose 3 abdominal distension 14.3% (placebo 0%) diarrhoea 14.3% (placebo 33.3%) dyspepsia 14.3% (placebo 0%) NCT06214052 · Phase 2 · combination · HIV · phase 2 Dose 3 dizziness 14.3% (placebo 0%) headache 14.3% (placebo 66.7%) influenza like illness 14.3% (placebo 0%) NCT06214052 · Phase 2 · combination · HIV · phase 2 |
Notes
- aTrial phases differ: Phase 2 versus Phase 3.
- bPopulation context differs: baseline_threshold differs (cd4>=200, hiv_viral_load>=3000 versus hiv_viral_load>=1000).
- cAssessment timepoints differ: 1.43 weeks versus 16 weeks.
- dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- ePopulation comparability has not been reviewed for 39 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Dolutegravir
show 12 more results
show 3 more results
show 52 more results
show 3 more results
show 1 more result
+ 80 further endpoints in the CSV export.
VH4524184
show 2 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dolutegravir's landscape · VH4524184's landscape